Novartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS
Source URL: https://qa1.novartis.us/news/media-releases/novartis-data-show-gilenya-had-significantly-greater-patient-retention-compared-idmts-relapsing-remitting-ms-0
List of links present in page
- https://qa1.novartis.us/news/media-releases/novartis-data-show-gilenya-had-significantly-greater-patient-retention-compared-idmts-relapsing-remitting-ms-0